FLT3 and acute myeloid leukemia: Furthermore, LT-171-861 was able to overcome known drug resistance induced by FLT3-ITD/F691L and FLT3-ITD/D835Y mutations, which limit the efficacy of AC220 and sorafenib in patients with AML.